TARGET (Translational Approaches for the Reversal Genetic Evaluation and Treatment) of Lung Cancer
Abstract
Smoking is a major cause for several types of cancer particularly lung cancer and cancers of the head and neck. Lung cancer is the leading cause of cancer death in both males and females in America, and is also the leading cause of cancer death worldwide. In America, it accounts for 28.5% of cancer deaths and 6.5% of all deaths. An estimated 173,700 Americans will develop lung cancer in 2004 and 160,440 will die from it. The vast majority (85%) of patients with lung cancer have non-small cell lung cancer (NSCLC) and across all stages of NSCLC, only 13.6% of males and 17.2% of women survive 5 years from diagnosis. More than 50% of cases are diagnosed at a late stage, for which the 5-year survival is only about 3%. White the death rate from head and neck cancer is not as high as from lung cancer, it also remains a major problem. Thus, to reduce lung cancer Incidence and mortality, we believe that developing novel effective therapeutic strategies that target both current and former smokers who are at risk for development of cancer is vital to achieving tangible progress in patient care. TARGET is focused on a series of complementary projects designed to obtain data in the preclinical and clinical settings to help us further understand the epidemiology of lung cancer, the molecular biology, genetics and epigenetics of lung cancer in the context of tobacco-damaged aerodigestive tract tissue, and the anti-cancer activity of several promising new agents, and various treatment and drug delivery approaches in models of lung cancer and other aerodigestive tract tumors.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2004
- Accession Number
- ADA428916
Entities
People
- Fadlo R. Khuri
- Waunki Hong
Organizations
- The University of Texas MD Anderson Cancer Center